Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × Crizotinib × Clear all

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Phase 2 Terminated

8 enrolled 16 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms